Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2016 - 2026)

Cumberland Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at $91967.0 for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 13.78% to $91967.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $476748.0, a 42.55% increase, with the full-year FY2025 number at $476748.0, up 42.55% from a year prior.
  • Interest & Investment Income hit $91967.0 in Q4 2025 for Cumberland Pharmaceuticals, down from $131583.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for CPIX hit a ceiling of $131583.0 in Q3 2025 and a floor of $5426.0 in Q1 2021.
  • Historically, Interest & Investment Income has averaged $61126.6 across 5 years, with a median of $59451.0 in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 81.85% in 2021 and later skyrocketed 585.1% in 2022.
  • Tracing CPIX's Interest & Investment Income over 5 years: stood at $6670.0 in 2021, then skyrocketed by 585.1% to $45696.0 in 2022, then soared by 77.26% to $81000.0 in 2023, then surged by 31.69% to $106667.0 in 2024, then fell by 13.78% to $91967.0 in 2025.
  • Business Quant data shows Interest & Investment Income for CPIX at $91967.0 in Q4 2025, $131583.0 in Q3 2025, and $127489.0 in Q2 2025.